Pancreatic Cancer Research

ResearcherUniversity of California, Los AngelesActive in the last 2 years

Shi‐He Liu

Verified by OpenAlex author ID and NIH RePORTER profile ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5060009087; NIH RePORTER profile ID 15083210. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
1
Labs led
1
Collaborators
22
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 4 papers · 2021: none · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 grant

Papers 11

  1. A PP2A-mtATR-tBid axis links DNA damage-induced CIP2A degradation to apoptotic dormancy and therapeutic resistance in PDAC. Co-author DOI 10.1016/j.canlet.2025.217790↗
  2. Smart exosomes enhance PDAC targeted therapy. Last author DOI 10.1016/j.jconrel.2024.02.037↗
  3. Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2020.08.002↗
  4. Kinome Array Profiling of Patient-Derived Pancreatic Ductal Adenocarcinoma Identifies Differentially Active Protein Tyrosine Kinases. Co-author DOI 10.3390/ijms21228679↗
  5. Emerging Kinase Therapeutic Targets in Pancreatic Ductal Adenocarcinoma and Pancreatic Cancer Desmoplasia. Co-author DOI 10.3390/ijms21228823↗
  6. Transcriptome sequencing analysis reveals unique and shared antitumor effects of three statins in pancreatic cancer. Co-author DOI 10.3892/or.2020.7810↗
  7. BIRC5 is a target for molecular imaging and detection of human pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.04.036↗
  8. A novel synthetic human insulin super promoter for targeting PDX-1-expressing pancreatic cancer. Co-author DOI 10.1016/j.canlet.2018.01.007↗
  9. Liposomal insulin promoter-thymidine kinase gene therapy followed by ganciclovir effectively ablates human pancreatic cancer in mice. First author DOI 10.1016/j.canlet.2015.01.002↗
  10. PDX-1 is a therapeutic target for pancreatic cancer, insulinoma and islet neoplasia using a novel RNA interference platform. Co-author DOI 10.1371/journal.pone.0040452↗
  11. PDX-1: demonstration of oncogenic properties in pancreatic cancer. Co-author DOI 10.1002/cncr.25629↗

Grants 1

  1. Engineering Exosome for Pancreatic Cancer Targeting Therapies R01CA276732↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Francis Charles Brunicardi · 10 shared papers, 2011–2024 · strength 0.92
  2. Justin F. Creeden · 5 shared papers, 2019–2024 · strength 0.61
  3. John J. Nemunaitis · 7 shared papers, 2011–2024 · strength 0.60
  4. Jingyuan Liu · 2 shared papers, 2024–2025 · strength 0.47
  5. Juehua Yu · 3 shared papers, 2018–2020 · strength 0.28
  6. Yibo Luo · 1 shared paper, 2025 · strength 0.27
  7. Yue Zou · 1 shared paper, 2025 · strength 0.27
  8. Donald Rao · 2 shared papers, 2012–2024 · strength 0.23
  9. Robert Erne McCullumsmith · 2 shared papers, 2020 · strength 0.22
  10. Jeffrey M. Sutton MD · 1 shared paper, 2020 · strength 0.10
  11. Cheng Yeh Chen · 1 shared paper, 2020 · strength 0.10
  12. Yu Xu · 1 shared paper, 2020 · strength 0.10
  13. Hongjin Wu · 1 shared paper, 2020 · strength 0.10
  14. Kunhua Wang · 1 shared paper, 2020 · strength 0.10
  15. Lei Zou · 1 shared paper, 2020 · strength 0.10
  16. James X. Wu · 1 shared paper, 2015 · strength 0.07
  17. Guisheng Zhou · 2 shared papers, 2011–2012 · strength 0.05
  18. Marie‐Claude Gingras · 2 shared papers, 2011–2012 · strength 0.05
  19. Min Li · 1 shared paper, 2011 · strength 0.03
  20. Changyi Chen · 1 shared paper, 2011 · strength 0.03
  21. William E. Fisher · 1 shared paper, 2012 · strength 0.03
  22. David W. Dawson · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.